Accumulating evidence indicates that smoking history is a poor prognostic factor in patients infected with COVID-19. Virus entry and activity are primarily related to the angiotensin-converting enzyme-2 \[ACE2\] receptor, which provides a human cell-binding site for the S protein of SARS-coronavirus \[SARS-CoV\], NL63-coronavirus, and SARS-CoV-2.^[@CIT0001]^ ACE2 is physiologically expressed by lung alveolar epithelial cells and plays an important regulatory role. The engagement between the virus and ACE2 appears to be associated with a dysregulation of ACE2, and could lead to acute lung injury. Smoking upregulates the ACE2 receptor,^[@CIT0001]^ probably explaining why these individuals are more susceptible to coronavirus infection.^[@CIT0002]^ Similarly, an elegant study demonstrated that the expression of the MERS-CoV receptor, dipeptidyl peptidase IV \[DPP4\], was upregulated in the lungs of smokers and chronic obstructive pulmonary disease patients, providing further data in favour of this theory.^[@CIT0002]^

Importantly, there are well-known opposing effects of smoking in ulcerative colitis \[UC\] and Crohn's disease \[CD\]. Indeed smoking has been demonstrated to be protective in UC, whereas in CD it has been shown to be associated with a more severe course. In line with previous reports, the percentage of active smokers was higher in CD than in UC patients \[3.5% versus 2%, respectively\] in the Wuhan inflammatory bowel disease \[IBD\] registry.^[@CIT0003]^ This difference partly explains why the overall mortality is slightly increased in CD patients with lung cancer or chronic obstructive pulmonary disease \[pooled standardised mortality ratio: (1.39, 95% confidence interval \[CI\]:1.30--1.50).^[@CIT0004]^

In a recent article by An and colleagues^[@CIT0003]^ on the measures adopted by the Wuhan IBD centre to prevent the spread of the new coronavirus \[SARS-CoV-2\], none of the 318 registered IBD patients reported COVID-19 infection.^[@CIT0003]^ More recently, in an Italian retrospective cohort study, no IBD patient was diagnosed with COVID-19 but smoking status was not assessed.^[@CIT0005]^ Based on these findings, we hypothesise that COVID-19 infection may be less severe in the overall population of UC patients than in those with CD, due to a lower rate of smokers. Ongoing large national and international registries on IBD patients infected with COVID-19 are needed to test this hypothesis and clarify the potential role of smoking in this patient population.
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